Fresh Tracks Therapeutics Inc (OTCPK:FRTX)
$ 0.74 -0.005 (-0.67%) Market Cap: 4.45 Mil Enterprise Value: -4.51 Mil PE Ratio: 0 PB Ratio: 0.45 GF Score: 52/100

Brickell Biotech Inc Long Term Safety Study Results for Sofpironium Bromide Gel Corporate Call Transcript

Apr 23, 2021 / 04:00PM GMT
Release Date Price: $41.87 (+4.89%)
Operator

Welcome, everyone, to the Brickell Biotech Phase III open-label long-term safety study data conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to Dan Ferry from LifeSci Advisors. Dan?

Daniel Ferry
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, and good afternoon, everyone. Joining us on today's call is Dr. Stacy Smith, Head of the California Dermatology and Clinical Research Institute and an investigator in the Phase III open-label, long-term safety study. Representing the company on today's call, we have Brickell's Chief Executive Officer, Rob Brown, and Chief R&D Officer, Deepak Chadha.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of this call. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot